ArticleFrontiers in oncology2025
Phenotypes of synovial fluid Treg cells in checkpoint blockade-related inflammatory arthritis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Checkpoint inhibitors create rogue regulatory T cells.The Journal of clinical investigation · 2026Article
- IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor-induced inflammatory arthritis.The Journal of clinical investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Regulatory T (Treg) cells may become dysregulated in checkpoint blockade-related inflammatory arthritis (CBIA), and we aimed to profile phenotypes and cytokine-secreting patterns of Tregs in CBIA. Methods: Using a 77-protein panel, we here profiled and compared single-cell membrane proteomics of Treg cells in synovial fluid (SF) in 15 patients with active CBIA onset, 12 patients with active rheumatoid arthritis (RA), and 9 CBI-treated cancer patients with non-autoimmune inflammatory knee swelling. Microbead-sorted Treg subsets from CBIA patients underwent 32-cytokine panel secretome analysis. Peripheral blood (PB) Tregs from seven CBIA and six RA patients were similarly analyzed. Findings were correlated with the modified Clinical Disease Activity Index (mCDAI) in CBIA patients. Results: Unsupervised clustering revealed two atypical immune-activating Treg cell clusters common to both CBIA and RA patients, in which an immunoactivating (featuring ICOS Conclusion: At the single-cell proteomic level, an atypical, MCP1/MCP4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.